

Predicting Diagnostic Delays in Persons with Multiple Sclerosis

Jinghong Jiangyang, BS; Justin C. Yu, BS; Farren B. S. Briggs, PhD, ScM

Neuroimmunological Disorders Gene-Environment Epidemiology (NDGE) Laboratory

Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University



Background

Diagnostic delays in multiple sclerosis (MS) negatively impacts long-term outcomes, as it delays the initiation of disease modifying therapies. In order to reduce treatment delays it is important to identify factors contributing to delays in the diagnosis of MS.

Objective: To identify predictors of diagnostic delays in MS


Materials & Methods

Study Population: 1,465 persons with MS (PwMS) from the Accelerated Cure Project (ACP; www.combouledcom,) were included in this study. ACP is an open-access repository of detailed epidemiologic data and blood-derived biospecimen samples of PwMS, other demyelinating diseases, and unaffected controls, recruited from 10 US neurology centers.

Outcome Definition: Diagnostic delay what the difference between age of diagnosis and age of onset (first symptom).

ZIG Model: A zero-inflated model has two parts: the 1st part assesses probability of a delay; the 2nd part assesses the relationship between predictors and delay length. Backward stepwise selection was used to determine predictors relevant for each part of the ZIG regression model, with robust standard errors.

Predictors: Variables included key demographics () and other relevant variables, including number of impaired functional domains (FDs: 1, 2-4, 5-8, ≥9; PwMS completed 30 questions on onset symptoms which were classified into 11 FDs: motor, cerebellar, brainstem/bulbar, etc), and era of onset (before 1983, 1983-2000, 2001-2004, ≥2005; to reflect landmark changes in diagnostic criteria). PwMS reported all comorbid conditions prior MS diagnosis. These conditions were grouped; e.g. hypercholesterolemia, hypertension, heat disease and Type 2 Diabetes were classified as vascular diseases (VD). We also grouped diseases into autoimmune diseases (AD), mental disorders (MD), neurological disorders (ND), cancers, and other physical diseases (OP).








Table 2: Goodness-of-fit comparisons for Zero-Inflated models

Model Comparison	ZINP	ZIG	ZINB
AIC		$\sqrt{}$	
BIC		$\sqrt{}$	$\sqrt{}$
Prediction Plot	$\sqrt{}$	$\sqrt{}$	
Zero Count Prediction	\checkmark		


Table 3: Results for fully adjusted models for diagnostic delay, including stratified associations by era of onset.

PREDICTORS		ONSET YEAR						
		<u>1956-2012</u> 1956-20						
J		1465		9	916		549	
		Coefficient	P-Value	Coefficient	P-Value	Coefficient	P-value	
			ro Inflation					
ntercept		-1.93	0.087	21.31	0.0047	-3.91	0.43	
Ige of onset		-0.0016	0.92	0.23	0.0040	-0.0019	0.98	
<u>/Iale</u>	White	-0.12 Ref	0.73	-0.91 Ref	0.54	5.28 Ref	0.016	
Race	Black	0.0084	 0.99	-14.04	NA	-9.32	 0.96	
	Other	-1.097	0.28	-6.75	0.96	-13.00	0.99	
/IS subtype PP		-2.79	0.34	-10.39	0.93	-2.13	0.26	
moker 5 years p	rior onset	0.15	0.63	-3.57	0.023	-8.70	0.013	
	ous mononucleosis		0.34	-3.55	0.17	6.63	0.0082	
· Diagnosis of obe		-0.57	0.27	-24.89	0.99	3.27	0.16	
ears of educatio	n	0.035	0.52	-2.13	0.0019	-0.48	0.055	
	0	0.27	0.67	-6.27	0.063	-0.21	0.96	
	1	Ref		Ref		Ref		
'Ds	2-4	1.18	0.0012	-2.64	0.026	1.36	0.37	
	5-8	1.014	0.024	-3.92	0.024	2.63	0.19	
	9-11	2.10	0.0017	-0.77	0.77	12.67	0.0022	
D comorbidity		0.091	0.81	-4.25	0.023	5.42	0.012	
ID comorbidity		-0.15	0.65	-2.02	0.28	-0.058	0.97	
ND comorbidity		0.12	0.70	-4.56	0.0073	-6.75	0.018	
Cancer comorbio	lity	-1.21	0.19	-18.96	0.99	-0.70	0.71	
OP comorbidity		-0.64	0.069	3.01	0.011	-7.71	0.011	
	1956-1983	-2.26	0.0021					
	1983-2000	-4.02	0.11	-1.36	0.28			
cra of onset	2001-2005	Ref		Ref		Ref		
				1/61				
	2006-2012	0.58	0.041			3.4	0.057	
		0.05	Count Mo			2.22		
ntercept		2.67	< 2*10 ⁻¹⁶	2.99	< 2*10 ⁻¹⁶	0.68	0.14	
lge of onset		-0.049	< 2*10 ⁻¹⁶	-0.037	< 2*10 ⁻¹⁶	-0.017	0.019	
<u>/Iale</u>	TX71. '4 -	-0.0050	0.95	0.032	0.73	0.2	0.19	
Race	White Black	Ref -0.35	0.0053	Ref -0.4	0.0052	Ref -0.60	0.013	
lace	Other	-0.52	0.033	-0. 4 -0.35	0.24	0.13	0.69	
/IS subtype PP		0.16	0.19	0.056	0.69	0.55	0.018	
moker 5 years p	rior onset	0.12	0.089	0.053	0.49	0.00068	0.99	
	ous mononucleosis		3.1*10-4	-2.89	5.7*10 ⁻⁴	0.27	0.053	
oiagnosis of obe	sity at onset	-0.42	9.4*10-4	-3.88	0.011	0.051	0.8	
ears of educatio	n	0.026	0.025	0.001	0.94	0.012	0.61	
	0	-0.0044	0.97	-0.098	0.45	-0.16	0.48	
	1	Ref		Ref		Ref		
'Ds	2-4	-0.085	0.27	-0.21	0.02	-0.29	0.043	
	5-8	-0.18	0.071	-0.28	0.016	-0.12	0.50	
	9-11	0.31	0.14	0.15	0.52	0.52	0.24	
D comorbidity		0.51	3.6*10 ⁻⁹	0.42	2.6*10 ⁻⁵	0.49	0.0052	
ID comorbidity		1.23	0.0072	0.28	0.0017	0.033	0.82	
ND comorbidity		0.21	0.11	0.12	0.17	-0.14	0.29	
Cancer comorbio	lity	0.23	0.11	0.22	0.24	0.45	0.067	
OP comorbidity		0.28	1.1*10-4	0.34	5.2*10 ⁻⁵	0.029	0.83	

Table 4: Results for reduced models (after backward stepwise selection)

ONSET YEAR

PREDICT	ORS	ONSET YEAR						
		1956-	2012	2001-2012				
N		1465		549				
		Coefficients	P-Value	Coefficients	P-Value			
		Zero Inflation N	Model					
Intercept		-1.72	2.2*10-7	-2.38	0.47			
Male				3.83	0.012			
Smoker 5 years prior	onset			-7.72	0.015			
History of infectious	mononucleosis			5.81	0.0016			
Diagnosis of obesity	at onset			1.36	0.44			
Years of education				-0.49	0.032			
	0	-0.032	0.96	-0.41	0.91			
	1	Ref		Ref				
FD s	2-4	1.17	0.0012	2.07	0.24			
	5-8	0.91	0.035	2.83	0.14			
	9-11	2.12	0.0013	12.69	0.0017			
VD comorbidity				3.71	0.024			
ND comorbidity				-4.28	0.02			
OP comorbidity		-0.58	0.074	-18.02	0.91			
	1956-1983	-2.28	0.0082					
Era of onset	1983-2000	-4.03	0.15					
	2001-2005	Ref		Ref				
	2006-2012	0.67	0.013	15.81	0.049			
		Count Mode						
Intercept		2.66	< 2*10 ⁻¹⁶	0.87	5*10 ⁻⁴			
Age of onset		-0.048	< 2*10 ⁻¹⁶	-0.016	0.017			
	White	Ref		Ref				
Race	Black	-0.36	0.0040	-0.58	0.015			
	Other	-0.46	0.047	0.19	0.55			
Smoker 5 years prior		1.12	0.11		0.040			
History of infectious		0.025	4.4*10-4	0.26	0.049			
Diagnosis of obesity	at onset	-0.39	0.0013					
Years of education		0.025	0.027					
	0	-0.0083	0.94	-0.16	0.46			
FD _a	2 4	Ref	 0 21	Ref	0.040			
FD s	2-4 5 0	-0.079	0.31	-0.28	0.049 0.37			
	5-8 9-11	-0.18 0.33	0.074 0.12	-0.16 0.54	0.37 0.25			
VD comorbidity	3-11	0.33	3.2*10 ⁻⁹	0.54	0.25 0.0058			
MD comorbidity		0.50	0.0044		0.0030			
ND comorbidity		0.22	0.0044					
Cancer comorbidity		0.12	0.11	 0.43	0.079			
OP comorbidity		0.28	8.2*10 ⁻⁵					
OF Collioration		0.40	0.4.10					



Conclusions

- The number of impaired FDs and era of onset were the only significant predictors of probability of a delay. Polysymptomatic PwMS were significantly more likely to have no delay than monosymptomatics (odds ratio (OR)2-4 FDs=3.0, p<0.01; OR5-8 FDs=2.6, p<0.05, and OR≥9 FDs=6.0, p<0.01). As expected, PwMS with more recent onset were more likely to also have no delay compared to those with onset in 1983-2000 (OR2001-2004=17.9; OR≥2005=34.1; p<<0.001).
- Length of diagnostic delay was influenced by multiple predictors. Older age of onset (p<<0.001), history of IM (p<0.01), being black (p<0.01) or other race (p<0.05), experienced shorter delays. Primary progressives had a 31% increase in delay length compared to relapsing at onset PwMS. There was suggestive evidence for a 13% increase in delay length among smokers (p<0.1).

We identified multiple predictors of probability of a diagnostic delay, and predictors contributing to the length of delay in PwMS.